{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-24-000125","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.016060+00:00","generated_at":"2026-05-31T12:57:28.102324+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioMarin Q2 revenue $712M (+20% YoY), GAAP EPS $0.55 (+90%), raises FY2024 guidance","bullets":["VOXZOGO revenue $183.9M (+62% YoY); ~3,500 children on treatment across 44 countries.","GAAP net income $107.2M (+91% YoY); Non-GAAP EPS $0.96 (+78% YoY) vs $0.54.","FY2024 guidance raised: total revenue, Non-GAAP operating margin, Non-GAAP EPS all increased.","ROCTAVIAN restructuring: focus on US, Germany, Italy; target $60M annual expenses by 2025; Q2 rev $7M.","Discontinued BMN 293 (gene therapy for hypertrophic cardiomyopathy); BMN 351/349/333 on track."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-24-000125","json":"https://secwatch.observer/filing/0001048477-24-000125.json","markdown":"https://secwatch.observer/filing/0001048477-24-000125.md","text":"https://secwatch.observer/filing/0001048477-24-000125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000125/0001048477-24-000125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000125/bmrn-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:57:28.102324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}